HMS Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

HMS Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$797K	Buy	+2,520	New	+$594K	0.3%	66
2017 Q1	–	Sell	-12,875	Closed	-$816K	–	149
2016 Q4	$816K	Sell	12,875 -3,727	-22%	-$235K	0.85%	55
2016 Q3	$1.06M	Buy	+16,602	New	+$1.22M	1.05%	30

Other funds holding LGND

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

MNBTD

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

HMS Capital Management's LGND Position: Q2 2026 in Review

HMS Capital Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 2,520 shares worth $797K. The stake represents 0.3% of the portfolio and ranks #66 among its holdings. This is a return to the name: HMS Capital Management previously reported a position in LGND as recently as Q4 2016.

HMS Capital Management first reported a position in LGND in Q3 2016 and has held it in 3 quarters since. The position peaked at $1.06M in Q3 2016. 57 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

HMS Capital Management held 2,520 shares of Ligand Pharmaceuticals worth $797K as of Q2 2026.
Ligand Pharmaceuticals was a new HMS Capital Management position in Q2 2026.
Ligand Pharmaceuticals made up 0.3% of HMS Capital Management's portfolio in Q2 2026, its #66 holding.
HMS Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 3 quarters since.
HMS Capital Management's Ligand Pharmaceuticals position peaked at $1.06M in Q3 2016.
57 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on HMS Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.